GW Pharmaceuticals' Cannabidiol For Seizures Wins UK Approval

  • The U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) has approved GW Pharmaceuticals' cannabidiol as an adjunctive treatment of seizures associated with tuberous sclerosis complex (TSC) for patients two years of age and older.
  • GW is a part of Jazz Pharmaceuticals plc JAZZ. Epidiolex/Epidyolex (cannabidiol) is a prescription, plant-derived cannabis-based medicine.
  • Concurrently, Jazz and Stand Up To Cancer (SU2C) have announced a three-year, $4 million research collaboration to explore new opportunities, including lurbinectedin in pediatric solid tumors and pan-RAF molecules in RAF- and RAS-mutated solid cancers. 
  • The collaboration between the companies will provide SU2C-funded researchers access to two Jazz molecules and funds to support one or more research projects over three years.
  • The collaboration may also support non-clinical studies of an investigational pan-RAF inhibitor compound called JZP815 in RAF- and RAS-mutated solid cancers.
  • Price Action: JAZZ shares are up 2.4% at $147.36 during the market session on the last check Tuesday.
  • Related content: Benzinga's Full FDA Calendar.
  • Photo by Rex Medlen from Pixabay


Meet the biggest cannabis industry players and make deals that will push the industry forward.

Featuring live company presentations, insider panels, and unmatched access to networking, the Benzinga Cannabis Capital Conference is where cannabis executives and entrepreneurs meet.

Join us September 13-14, 2022 at The Palmer House in Chicago, IL.

Posted In: BriefsBiotechCannabisNewsHealth CareContractsFDAMarketsGeneral